$ENVB
Enveric Biosciences, Inc. Stock $envb

$envb Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000149315224031352 Filed on August 12, 2024

Income Statement

Concept	2024 Q3	2024 Q2	2023 Q2
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.236M	$1.298M	$3.155M
YoY Change	-38.52%	-58.88%	26.15%
% of Gross Profit
Research & Development	$762.7K	$515.5K	$2.513M
YoY Change	-43.58%	-79.49%	18.54%
% of Gross Profit
Depreciation & Amortization	$42.63K	$42.59K	$44.33K
YoY Change	-3.35%	-3.93%	2.35%
% of Gross Profit
Operating Expenses	$762.7K	$515.5K	$2.513M
YoY Change	-43.58%	-79.49%	18.54%
Operating Profit	-$2.083M	-$1.898M	-$5.755M
YoY Change	-39.59%	-67.02%	22.27%
Interest Expense	-$720.00	$7.730K	-$367.2K
YoY Change	-100.13%	-102.1%	-55074.55%
% of Operating Profit
Other Income/Expense, Net	-$840.00	$18.54K	-$601.0K
YoY Change	-100.13%	-103.08%	-131.37%
Pretax Income	-$2.084M	-$1.879M	-$6.356M
YoY Change	-25.98%	-70.43%	127.77%
Income Tax
% Of Pretax Income
Net Earnings	-$2.084M	-$1.879M	-$6.356M
YoY Change	-26.16%	-70.43%	127.77%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.24	-$0.25	-$3.04
Diluted Earnings Per Share	-$0.24	-$0.25	-$3.04
COMMON SHARES
Basic Shares Outstanding	8.920M shares	7.752M shares	2.078M shares
Diluted Shares Outstanding	8.703M shares	7.588M shares	2.108M shares

Balance Sheet

Concept	2024 Q3	2024 Q2	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$3.112M	$3.503M	$7.081M
YoY Change	-27.13%	-50.54%	-60.68%
Cash & Equivalents	$3.112M	$3.503M	$7.081M
Short-Term Investments
Other Short-Term Assets	$1.209M	$1.718M	$1.819M
YoY Change	-22.51%	-5.53%	33.69%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$4.338M	$5.520M	$8.900M
YoY Change	-25.55%	-37.98%	-54.05%
LONG-TERM ASSETS
Property, Plant & Equipment	$367.7K	$405.1K	$595.2K
YoY Change	-31.8%	-31.94%	-24.02%
Goodwill			$295.3K
YoY Change			-81.09%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$452.1K	$531.7K	$900.2K
YoY Change	-42.94%	-40.94%	-90.22%
TOTAL ASSETS
Total Short-Term Assets	$4.338M	$5.520M	$8.900M
Total Long-Term Assets	$452.1K	$531.7K	$900.2K
Total Assets	$4.790M	$6.052M	$9.800M
YoY Change	-27.63%	-38.25%	-65.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$576.3K	$459.9K	$1.234M
YoY Change	-47.52%	-62.75%	63.66%
Accrued Expenses	$253.2K	$176.4K	$1.499M
YoY Change	-83.5%	-88.24%	49.31%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$839.2K	$645.3K	$4.926M
YoY Change	-79.94%	-86.9%	111.89%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change			-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$839.2K	$645.3K	$4.926M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$839.2K	$645.3K	$4.926M
YoY Change	-79.92%	-86.9%	-17.47%
SHAREHOLDERS EQUITY
Retained Earnings	-$102.9M	-$100.8M	-$90.24M
YoY Change	10.59%	11.74%	32.61%
Common Stock	$89.95K	$78.79K	$21.42K
YoY Change	312.27%	267.86%	103.2%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$3.951M	$5.406M	$4.875M
YoY Change
Total Liabilities & Shareholders Equity	$4.790M	$6.052M	$9.800M
YoY Change	-27.63%	-38.25%	-65.7%

Cashflow Statement

Concept	2024 Q3	2024 Q2	2023 Q2
OPERATING ACTIVITIES
Net Income	-$2.084M	-$1.879M	-$6.356M
YoY Change	-26.16%	-70.43%	127.77%
Depreciation, Depletion And Amortization	$42.63K	$42.59K	$44.33K
YoY Change	-3.35%	-3.93%	2.35%
Cash From Operating Activities	-$927.1K	-$2.889M	-$4.466M
YoY Change	-66.17%	-35.31%	-2.6%
INVESTING ACTIVITIES
Capital Expenditures		$0.00	$20.00
YoY Change		-100.0%	-100.04%
Acquisitions
YoY Change
Other Investing Activities		$4.495M	$16.87K
YoY Change		26542.68%
Cash From Investing Activities		$0.00	$16.86K
YoY Change		-100.0%	-131.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	517.7K	34.43K	-1.052M
YoY Change	-570.63%	-103.27%	-209.81%
NET CHANGE
Cash From Operating Activities	-927.1K	-2.889M	-4.466M
Cash From Investing Activities		0.000	16.86K
Cash From Financing Activities	517.7K	34.43K	-1.052M
Net Change In Cash	-409.4K	-2.855M	-5.501M
YoY Change	-85.64%	-48.11%	49.44%
FREE CASH FLOW
Cash From Operating Activities	-$927.1K	-$2.889M	-$4.466M
Capital Expenditures		$0.00	$20.00
Free Cash Flow		-$2.889M	-$4.466M
YoY Change		-35.31%	-1.44%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38286
	dei	Entity Registrant Name EntityRegistrantName	ENVERIC BIOSCIENCES, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	95-4484725
	dei	Entity Address Address Line1 EntityAddressAddressLine1	4851 Tamiami Trail N
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 200
	dei	Entity Address City Or Town EntityAddressCityOrTown	Naples
	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	34103
	dei	City Area Code CityAreaCode	(239)
	dei	Local Phone Number LocalPhoneNumber	302-1707
	dei	Security12b Title Security12bTitle	Common Stock, $0.01 par value per share
	dei	Trading Symbol TradingSymbol	ENVB
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-1879394	usd
CY2024Q2	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent		usd
CY2024Q2	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests		usd
CY2024Q2	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2024Q2	us-gaap	Stockholders Equity Note Subscriptions Receivable StockholdersEquityNoteSubscriptionsReceivable		usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2017383	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	5519934	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	405114	usd
CY2024Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	531670	usd
CY2024Q2	us-gaap	Assets Assets	6051604	usd
CY2024Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	459898	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	176373	usd
CY2024Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	4443	usd
CY2024Q2	ENVB	Warrant Liabilities Current WarrantLiabilitiesCurrent	4626	usd
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7878568	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7878568	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2739315	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2739315	shares
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	78785	usd
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	106729801	usd
CY2023Q4	us-gaap	Stockholders Equity Note Subscriptions Receivable StockholdersEquityNoteSubscriptionsReceivable	1817640	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-100835827	usd
CY2024Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-566495	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	5406264	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6051604	usd
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Central Index Key EntityCentralIndexKey	0000890821
CY2024Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q2	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet		usd
CY2024Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2024Q2	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact		usd
CY2024Q2	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment		usd
CY2024Q2	ENVB	Stock Issued During Period Value Common Stock Sold Under Equity Distribution StockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution		usd
CY2024Q2	ENVB	Stock Issued During Period Value Issuance Of Common Shares For Vested Restricted Stock Units StockIssuedDuringPeriodValueIssuanceOfCommonSharesForVestedRestrictedStockUnits		usd
CY2023Q2	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue		usd
CY2023Q2	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits		usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet		usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense		usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		usd
	ENVB	Increase Decrease In Rightofuse Operating Lease Asset And Obligation IncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation		usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment		usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants		usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
	ENVB	Proceeds From Common Stock Sold Under Purchase Agreement Net Of Offering Costs ProceedsFromCommonStockSoldUnderPurchaseAgreementNetOfOfferingCosts		usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts		usd
	us-gaap	Payments For Repurchase Of Redeemable Preferred Stock PaymentsForRepurchaseOfRedeemablePreferredStock		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	ENVB	Offering Costs Accrued Not Paid OfferingCostsAccruedNotPaid		usd
	ENVB	Deferred Offering Costs Charged To Offering Costs DeferredOfferingCostsChargedToOfferingCosts		usd
	ENVB	Issuance Of Common Shares For Deferred Offering Costs IssuanceOfCommonSharesForDeferredOfferingCosts		usd
	ENVB	Preferred Dividends Attributable To Redeemable Noncontrolling Interest PreferredDividendsAttributableToRedeemableNoncontrollingInterest		usd
	ENVB	Accretion Of Embedded Derivative To Redemption Value AccretionOfEmbeddedDerivativeToRedemptionValue		usd
CY2024Q2	ENVB	Accrued Restructuring Costs AccruedRestructuringCosts		usd
CY2024Q2	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent		usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
	ENVB	Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2024Q2	us-gaap	Restructuring And Related Cost Cost Incurred To Date1 RestructuringAndRelatedCostCostIncurredToDate1		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	8919920	shares
	dei	Entity Listing Par Value Per Share EntityListingParValuePerShare	0.01
CY2024Q2	us-gaap	Cash Cash	3502551	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	126556	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	645340	usd
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2024Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1297651	usd
CY2024Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	515501	usd
CY2024Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	84779	usd
CY2024Q2	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	1897931	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1897931	usd
CY2024Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-10805	usd
CY2024Q2	us-gaap	Gain Loss On Investments GainLossOnInvestments	7767	usd
CY2023Q2	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	714000	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	727000	usd
CY2024Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-35	usd
CY2024Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	18537	usd
CY2024Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1879394	usd
CY2023Q2	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	6712	usd
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	19041	usd
CY2023Q2	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	36997	usd
	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	147988	usd
CY2024Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1879394	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-14652	usd
CY2024Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1894046	usd
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.25
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.25
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.04
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.04
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.75
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.75
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.35
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5.35
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7587851	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7587851	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2107583	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2107583	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5794653	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5794653	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2093008	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2093008	shares
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	1956336	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	351488	usd
CY2024Q1	ENVB	Common Stock Equity Distribution Costs CommonStockEquityDistributionCosts	583713	usd
CY2024Q1	ENVB	Stock Issued During Period Value Common Stock Sold Under Equity Distribution StockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution	1808789	usd
CY2024Q1	ENVB	Stock Issued During Period Value Issued Direct Offering Net Of Offering Cost StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost	322453	usd
CY2024Q1	ENVB	Stock Issued During Period Value Exercise Of Inducement Warrants For Common Stock StockIssuedDuringPeriodValueExerciseOfInducementWarrantsForCommonStock	2676980	usd
CY2024Q1	ENVB	Net Offering Costs NetOfferingCosts	12821	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	267679	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	1537140	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	17906	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-2456915	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	6481856	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	369614	usd
CY2024Q2	ENVB	Common Stock Equity Distribution Costs CommonStockEquityDistributionCosts	82850	usd
CY2024Q2	ENVB	Stock Issued During Period Value Issued Direct Offering Net Of Offering Cost StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost	448840	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-14652	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-1879394	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	5406264	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	14671924	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	532835	usd
CY2023Q1	ENVB	Preferred Dividends Attributable To Redeemable Noncontrolling Interest PreferredDividendsAttributableToRedeemableNoncontrollingInterest	12329	usd
CY2023Q1	ENVB	Accretion Of Embedded Derivative To Redemption Value AccretionOfEmbeddedDerivativeToRedemptionValue	110991	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	1968	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	10405880	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	10405880	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	879738	usd
CY2023Q2	ENVB	Preferred Dividends Attributable To Redeemable Noncontrolling Interest PreferredDividendsAttributableToRedeemableNoncontrollingInterest	6712	usd
CY2023Q2	ENVB	Accretion Of Embedded Derivative To Redemption Value AccretionOfEmbeddedDerivativeToRedemptionValue	36997	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-11286	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-6356053	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	4874570	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	4874570	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4336309	usd
	us-gaap	Net Income Loss NetIncomeLoss	-11033580	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-20844	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	183164	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	19165	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	-962636	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	727000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	721102	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1412573	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	54703	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	84376	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	84375	usd
	us-gaap	Depreciation Depreciation	85812	usd
	us-gaap	Depreciation Depreciation	88629	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	4212	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	543822	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1111913	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1458670	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	542397	usd
	ENVB	Increase Decrease In Rightofuse Operating Lease Asset And Obligation IncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation	54702	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5487520	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9602930	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5187	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	16872	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	11685	usd
	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants	1804819	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	2676980	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2290186	usd
	ENVB	Proceeds From Common Stock Sold Under Purchase Agreement Net Of Offering Costs ProceedsFromCommonStockSoldUnderPurchaseAgreementNetOfOfferingCosts	82026	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	161312	usd
	us-gaap	Payments For Repurchase Of Redeemable Preferred Stock PaymentsForRepurchaseOfRedeemablePreferredStock	1052057	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6692699	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1052057	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	9395	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	826	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1214574	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-10642476	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2287977	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	17723884	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3502551	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	7081408	usd
	us-gaap	Interest Paid Net InterestPaidNet	11	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	24001	usd
	ENVB	Offering Costs Accrued Not Paid OfferingCostsAccruedNotPaid	149	usd
	ENVB	Deferred Offering Costs Charged To Offering Costs DeferredOfferingCostsChargedToOfferingCosts	240969	usd
	ENVB	Issuance Of Common Shares For Deferred Offering Costs IssuanceOfCommonSharesForDeferredOfferingCosts	771293	usd
	ENVB	Preferred Dividends Attributable To Redeemable Noncontrolling Interest PreferredDividendsAttributableToRedeemableNoncontrollingInterest	19041	usd
	ENVB	Accretion Of Embedded Derivative To Redemption Value AccretionOfEmbeddedDerivativeToRedemptionValue	147988	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_808_eus-gaap--NatureOfOperations_zSp0JnikuGGf" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1. <span id="xdx_820_znvS3Xd1cWVh">BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nature of Operations</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enveric Biosciences, Inc. (“Enveric” or the “Company”) is a biotechnology company developing novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. The head office of the Company is located in Naples, Florida. The Company has the following wholly-owned subsidiaries: Jay Pharma Inc. (“Jay Pharma”), 1306432 B.C. Ltd., MagicMed Industries, Inc. (“MagicMed”), Enveric Biosciences Canada, Inc., Akos Biosciences, Inc. (“Akos”), and Enveric Therapeutics, Pty. Ltd. (“Enveric Therapeutics”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leveraging its unique discovery and development platform, The Psybrary™, Enveric has created a robust intellectual property portfolio of new chemical entities for specific mental health indications. Enveric’s lead program, the EVM201 Series, comprises next generation synthetic prodrugs of the active metabolite, psilocin. Enveric is developing the first product from the EVM201 Series – EB-002 (formerly EB-373) – for the treatment of psychiatric disorders. Enveric is also advancing its product EB-003 from the EVM301 Series, which is expected to offer a first-in-class, new approach to the treatment of difficult-to-address mental health disorders, mediated by the promotion of neuroplasticity without also inducing hallucinations in the patient.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has continued to pursue the development of MagicMed’s proprietary Psychedelic Derivatives library, the Psybrary™ which the Company believes will help to identify and develop the right drug candidates needed to address mental health challenges, including cancer-related distress. The Company synthesizes novel versions of classic psychedelics, such as psilocybin, N,N-Dimethyltryptamine (“DMT”), mescaline and MDMA, using a mixture of chemistry and synthetic biology, resulting in the expansion of the Psybrary™, which includes 15 patent families with over a million potential variations and hundreds of synthesized molecules. Within the Psybrary™ the Company has three different types of molecules, Generation 1 (classic psychedelics), Generation 2 (new chemical entity pro-drugs of psilocin), and Generation 3 (new chemical entity analogs). The Company has created over 1000 novel psychedelic molecular compounds and derivatives that are housed in the Psybrary™. The Company’s current focus is to develop its lead molecules, EB-002 and EB-003, and to outlicense other molecules from the Psybrary™.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company screens newly synthesized molecules in the Psybrary™ through PsyAI™, a proprietary artificial intelligence (“AI”) tool. Leveraging AI systems is expected to reduce the time and cost of pre-clinical, clinical, and commercial development. The Company believes it streamlines pharmaceutical design by predicting ideal binding structures of molecules, manufacturing capabilities, and pharmacological effects to help determine ideal drug candidates, tailored to each indication. Each of these molecules that the Company believes are patentable can then be further screened to see how changes to its makeup alter its effects in order to synthesize additional new molecules. New compounds of sufficient purity are undergoing pharmacological screening, including non-clinical (receptors/cell lines), preclinical (animal), and ultimately clinical (human) evaluations. The Company intends to utilize the Psybrary™ and the AI tool to categorize and characterize the Psybrary™ substituents to focus on bringing more psychedelics-inspired molecules from discovery to the clinical phase.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Going Concern, Liquidity and Other Uncertainties</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has incurred a loss since inception resulting in an accumulated deficit of $<span id="xdx_908_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_di_c20240630_zIwV4E4NL3Ee" title="Accumulated deficit">100,835,827 </span>as of June 30, 2024, and further losses are anticipated in the development of its business. For the six months ended June 30, 2024, the Company has operating cash outflows of $<span id="xdx_90E_eus-gaap--NetCashProvidedByUsedInOperatingActivities_di_c20240101__20240630_zPEfgwpHjsOb" title="Net cash used in operating activities">5,487,520</span> and had a loss from operations of $<span id="xdx_901_eus-gaap--OperatingIncomeLoss_di_c20240101__20240630_zjWsRFNtuuk9" title="Loss from operations">4,375,248</span>. Being a research and development company, since inception, the Company has not yet generated revenue and the Company has incurred continuing losses from its operations. The Company’s operations have been funded principally through the issuance of equity. These factors raise substantial doubt about the Company’s ability to continue as a going concern for a period of one year from the issuance of these unaudited condensed consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In assessing the Company’s ability to continue as a going concern, the Company monitors and analyzes its cash and its ability to generate sufficient cash flow in the future to support its operating and capital expenditure commitments. At June 30, 2024, the Company had cash of $<span id="xdx_903_eus-gaap--Cash_iI_c20240630_zWAgXtJ7eQya" title="Cash">3,502,551</span> and working capital of $<span id="xdx_90E_ecustom--WorkingCapital_iI_c20240630_zgtgRn26M1X5" title="Working capital">4,874,594</span>. The Company’s current cash on hand is not sufficient to satisfy its operating cash needs for the 12 months from the filing of this Quarterly Report on Form 10-Q. These conditions raise substantial doubt regarding the Company’s ability to continue as a going concern for a period of one year after the date the financial statements are issued. Management’s plan to alleviate the conditions that raise substantial doubt include raising additional working capital through public or private equity or debt financings or other sources, the Purchase Agreement with Lincoln Park (see Note 7 and 9), subject to registration, and may include additional collaborations with third parties as well as disciplined cash spending. Adequate additional financing may not be available to us on acceptable terms, or at all. Should the Company be unable to raise sufficient additional capital, the Company may be required to undertake cost-cutting measures including delaying or discontinuing certain operating activities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a result of these factors, management has concluded that there is substantial doubt about the Company’s ability to continue as a going concern for a period of one year after the date of the unaudited condensed consolidated financial statements are issued. The Company’s unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Inflation Risks</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company considers the current inflationary trend existing in the North American economic environment reasonably likely to have a material unfavorable impact on results of continuing operations. Higher rates of price inflation, as compared to recent prior levels of price inflation, have caused a general increase in the cost of labor and materials. In addition, there is an increased risk of the Company experiencing labor shortages due to a potential inability to attract and retain human resources due to increased labor costs resulting from the current inflationary environment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nasdaq Notice</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 21, 2023, the Company received a letter from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) stating that as of September 30, 2023, the Company did not meet the minimum of $<span id="xdx_90F_ecustom--MinimumOfStockholdersEquityRequiredForContinuedListingPursuantToExchange_iI_c20231121_zyrVF6wiwItd" title="Minimum of stockholders equity required for continued listing pursuant to exchange">2,500,000</span> in stockholders’ equity required for continued listing pursuant to Nasdaq Listing Rule 5550(b)(1). On February 6, 2024, the Company received a letter from Nasdaq, granting the Company an extension to regain compliance with the minimum stockholders’ equity requirement by May 20, 2024. On May 21, 2024, the Company received a letter from Nasdaq notifying the Company that it regained compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 16, 2024, the Company received a letter from Nasdaq’s Listing Qualifications Department stating that because the closing bid price for the Company’s common stock listed on Nasdaq was below $<span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20240516_zNJqOy8vzea8" title="Shares issued price">1.00</span> for 30 consecutive business days, the Company no longer meets the minimum bid price requirement for continued listing on the Nasdaq Capital Market (the “Minimum Bid Price Requirement”). The Company has a period of 180 calendar days from May 16, 2024, or until November 12, 2024, to regain compliance with the Minimum Bid Price Requirement. If at any time before November 12, 2024, the bid price of the Company’s common stock closes at or above $<span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20231112_zv4AL7YnmPP5" title="Shares issued price">1.00</span> per share for a minimum of 10 consecutive business days, Nasdaq will provide written notification that the Company has achieved compliance with the Minimum Bid Price Requirement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-100835827	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5487520	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4375248	usd
CY2024Q2	us-gaap	Cash Cash	3502551	usd
CY2024Q2	ENVB	Working Capital WorkingCapital	4874594	usd
CY2023Q4	ENVB	Minimum Of Stockholders Equity Required For Continued Listing Pursuant To Exchange MinimumOfStockholdersEquityRequiredForContinuedListingPursuantToExchange	2500000	usd
CY2024Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	1.00
CY2023Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	1.00
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_842_eus-gaap--UseOfEstimates_zLEH7hToV6z3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zCotIUv4J8D">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities at the date of the financial statements and expenses during the periods reported. By their nature, these estimates are subject to measurement uncertainty and the effects on the financial statements of changes in such estimates in future periods could be significant. Significant areas requiring management’s estimates and assumptions include determining the fair value of transactions involving common stock, the valuation of warrants and preferred investment options, and the valuation of stock-based compensation and accruals associated with third party providers supporting research and development efforts. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_845_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zVDN5PPareGj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zMqdJ35VECCc">Reclassification</span> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain reclassifications have been made to the prior period’s unaudited condensed consolidated financial statements in order to conform to the current year presentation. In the prior year, the Company included certain investor related expenses were included within research and development on the unaudited condensed consolidated statements of operations. These expenses were reclassified to general and administrative expenses in the current year. This reclassification had no effect on the Company’s previously reported results of operations, changes in equity, or cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_847_eus-gaap--ConcentrationRiskCreditRisk_zymZi2SHHrDf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zbnBcoX1DXji">Concentration of Credit Risk</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which at times, may exceed the federal depository insurance coverage of $<span id="xdx_904_eus-gaap--CashFDICInsuredAmount_iI_c20240630__srt--StatementGeographicalAxis__country--US_zp920NPY5HRj" title="Cash FDIC insured amount">250,000</span> in the United States and Australia and $<span id="xdx_902_eus-gaap--CashFDICInsuredAmount_iI_c20240630__srt--StatementGeographicalAxis__country--CA_zZ8C1lr4SWd5" title="Cash insured amount">100,000</span> in Canada. The Company has not experienced losses on these accounts, and management believes the Company is not exposed to significant risks on such accounts. As of June 30, 2024, the Company had greater than $<span id="xdx_908_eus-gaap--CashFDICInsuredAmount_iI_c20240630__srt--StatementGeographicalAxis__country--US_zcPWOA02shmb" title="Cash FDIC insured amount">250,000</span> at United States financial institutions, less than $<span id="xdx_901_eus-gaap--CashFDICInsuredAmount_iI_c20240630__srt--StatementGeographicalAxis__country--AU_zHgQ7CFEvj8d" title="Cash FDIC insured amount">250,000</span> at Australian financial institutions, and less than $<span id="xdx_909_eus-gaap--CashFDICInsuredAmount_iI_c20240630__srt--StatementGeographicalAxis__country--CA_z2zR7upc3nWh" title="Cash FDIC insured amount">100,000</span> at Canadian financial institutions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p>
CY2024Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1336312	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1336312	shares
CY2023Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1998487	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1998487	shares
CY2024Q2	ENVB	Prepaid Research And Development PrepaidResearchAndDevelopment	257218	usd
CY2023Q4	ENVB	Prepaid Research And Development PrepaidResearchAndDevelopment	46320	usd
CY2024Q2	us-gaap	Prepaid Taxes PrepaidTaxes	241269	usd
CY2023Q4	us-gaap	Prepaid Taxes PrepaidTaxes	243429	usd
CY2024Q2	us-gaap	Prepaid Insurance PrepaidInsurance	375215	usd
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	149559	usd
CY2024Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	81192	usd
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	62036	usd
CY2024Q2	us-gaap	Deferred Offering Costs DeferredOfferingCosts	763173	usd
CY2023Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	567603	usd
CY2024Q2	ENVB	Prepaid Franchise Tax Receivable PrepaidFranchiseTaxReceivable	38258	usd
CY2023Q4	ENVB	Prepaid Franchise Tax Receivable PrepaidFranchiseTaxReceivable	79258	usd
CY2024Q2	ENVB	Prepaid Research And Development Tax Incentive Receivable PrepaidResearchAndDevelopmentTaxIncentiveReceivable	261058	usd
CY2023Q4	ENVB	Prepaid Research And Development Tax Incentive Receivable PrepaidResearchAndDevelopmentTaxIncentiveReceivable	145349	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2017383	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1293554	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	210932	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	84376	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	126556	usd
CY2024Q2	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
CY2023Q2	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
CY2024Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	42188	usd
CY2023Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	42187	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	84376	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	84375	usd
CY2024Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	430831	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	357711	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	405114	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	507377	usd
CY2024Q2	us-gaap	Depreciation Depreciation	42591	usd
CY2023Q2	us-gaap	Depreciation Depreciation	44331	usd
	us-gaap	Depreciation Depreciation	85812	usd
	us-gaap	Depreciation Depreciation	88629	usd
CY2024Q2	ENVB	Accrued Product Development Cost AccruedProductDevelopmentCost	79197	usd
CY2023Q4	ENVB	Accrued Product Development Cost AccruedProductDevelopmentCost	139981	usd
CY2024Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	8634	usd
CY2023Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	8889	usd
CY2024Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	70542	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	584810	usd
CY2023Q4	ENVB	Accrued Restructuring Costs AccruedRestructuringCosts	301645	usd
CY2023Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	22318	usd
CY2024Q2	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	18000	usd
CY2023Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	18000	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	176373	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1075643	usd
CY2024Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1817640	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	30329	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	57.17
CY2023Q4	ENVB	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue	77.22
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y4M24D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	7247	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	39.35
	ENVB	Share Based Compensation Arrangement By Share Based Payment Award Options Expired Forfeited Or Cancelled Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue	54.02
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	23082	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	62.77
CY2024Q2	ENVB	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue	84.51
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P2Y10M24D
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	21988	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	65.74
CY2024Q2	ENVB	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue	88.59
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P2Y6M
CY2024Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	369200	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	825363	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	727370	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1310112	usd
CY2024Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	369200	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	825363	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	727370	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1310112	usd
CY2024Q2	ENVB	Prepaid Research And Development Tax Incentive Receivable PrepaidResearchAndDevelopmentTaxIncentiveReceivable	261058	usd
CY2023Q4	ENVB	Prepaid Research And Development Tax Incentive Receivable PrepaidResearchAndDevelopmentTaxIncentiveReceivable	145349	usd
CY2023Q2	ENVB	Reduction In Force Restructuring Percentage ReductionInForceRestructuringPercentage	0.35	pure
CY2023Q4	us-gaap	Restructuring And Related Cost Cost Incurred To Date1 RestructuringAndRelatedCostCostIncurredToDate1	301645	usd
	us-gaap	Restructuring Costs RestructuringCosts	-301645	usd

Files In Submission

Name	View Source	Status
envb-20240630_cal.xml	Edgar Link	unprocessable
0001493152-24-031352-index-headers.html	Edgar Link	pending
0001493152-24-031352-index.html	Edgar Link	pending
0001493152-24-031352.txt	Edgar Link	pending
0001493152-24-031352-xbrl.zip	Edgar Link	pending
envb-20240630.xsd	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
envb-20240630_def.xml	Edgar Link	unprocessable
envb-20240630_lab.xml	Edgar Link	unprocessable
envb-20240630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ENVB
Enveric Biosciences, Inc. Stock $envb

2024 Q3 Form 10-Q Financial Statement

#000149315224031352 Filed on August 12, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ENVB Enveric Biosciences, Inc. Stock $envb

2024 Q3 Form 10-Q Financial Statement

#000149315224031352 Filed on August 12, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ENVB
Enveric Biosciences, Inc. Stock $envb